198 related articles for article (PubMed ID: 38416633)
1. Pulmonary arterial hypertension treatment: an individual participant data network meta-analysis.
Moutchia J; McClelland RL; Al-Naamani N; Appleby DH; Holmes JH; Minhas J; Mazurek JA; Palevsky HI; Ventetuolo CE; Kawut SM
Eur Heart J; 2024 Jun; 45(21):1937-1952. PubMed ID: 38416633
[TBL] [Abstract][Full Text] [Related]
2. Prostacyclin for pulmonary arterial hypertension.
Barnes H; Yeoh HL; Fothergill T; Burns A; Humbert M; Williams T
Cochrane Database Syst Rev; 2019 May; 5(5):CD012785. PubMed ID: 31042010
[TBL] [Abstract][Full Text] [Related]
3. A Bayesian Network Meta-analysis of Add-on Drug Therapies Specific for Pulmonary Arterial Hypertension.
Petrovič M; Locatelli I
Ann Pharmacother; 2020 May; 54(5):423-433. PubMed ID: 31735058
[No Abstract] [Full Text] [Related]
4. Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review.
Ruopp NF; Cockrill BA
JAMA; 2022 Apr; 327(14):1379-1391. PubMed ID: 35412560
[TBL] [Abstract][Full Text] [Related]
5. Is low-risk status a surrogate outcome in pulmonary arterial hypertension? An analysis of three randomised trials.
Blette BS; Moutchia J; Al-Naamani N; Ventetuolo CE; Cheng C; Appleby D; Urbanowicz RJ; Fritz J; Mazurek JA; Li F; Kawut SM; Harhay MO
Lancet Respir Med; 2023 Oct; 11(10):873-882. PubMed ID: 37230098
[TBL] [Abstract][Full Text] [Related]
6. Combination Therapy in Pulmonary Arterial Hypertension-Targeting the Nitric Oxide and Prostacyclin Pathways.
Mandras S; Kovacs G; Olschewski H; Broderick M; Nelsen A; Shen E; Champion H
J Cardiovasc Pharmacol Ther; 2021 Sep; 26(5):453-462. PubMed ID: 33836637
[TBL] [Abstract][Full Text] [Related]
7. Comparison of inhaled nitric oxide with aerosolized prostacyclin or analogues for the postoperative management of pulmonary hypertension: a systematic review and meta-analysis.
Chen SH; Chen LK; Teng TH; Chou WH
Ann Med; 2020; 52(3-4):120-130. PubMed ID: 32204626
[No Abstract] [Full Text] [Related]
8. A focus on riociguat in the treatment of pulmonary arterial hypertension.
Toxvig AK; Wehland M; Grimm D; Infanger M; Krüger M
Basic Clin Pharmacol Toxicol; 2019 Sep; 125(3):202-214. PubMed ID: 31206240
[TBL] [Abstract][Full Text] [Related]
9. BMI and Treatment Response in Patients With Pulmonary Arterial Hypertension: A Meta-analysis.
McCarthy BE; McClelland RL; Appleby DH; Moutchia JS; Minhas JK; Min J; Mazurek JA; Smith KA; Fritz JS; Pugliese SC; Urbanowicz RJ; Holmes JH; Palevsky HI; Kawut SM; Al-Naamani N
Chest; 2022 Aug; 162(2):436-447. PubMed ID: 35247393
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial.
Jing ZC; Parikh K; Pulido T; Jerjes-Sanchez C; White RJ; Allen R; Torbicki A; Xu KF; Yehle D; Laliberte K; Arneson C; Rubin LJ
Circulation; 2013 Feb; 127(5):624-33. PubMed ID: 23307827
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of oral therapies targeting the prostacyclin pathway in pulmonary arterial hypertension: A systematic review and network meta-analysis.
Manzi G; Mariani MV; Filomena D; Recchioni T; Papa S; Scoccia G; Badagliacca R; Vizza CD
Vascul Pharmacol; 2024 Mar; 154():107280. PubMed ID: 38309551
[TBL] [Abstract][Full Text] [Related]
12. Phosphodiesterase 5 inhibitors for pulmonary hypertension.
Barnes H; Brown Z; Burns A; Williams T
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD012621. PubMed ID: 30701543
[TBL] [Abstract][Full Text] [Related]
13. Inhaled treprostinil: a therapeutic review.
Channick RN; Voswinckel R; Rubin LJ
Drug Des Devel Ther; 2012; 6():19-28. PubMed ID: 22291467
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Treatment Response in Idiopathic and Connective Tissue Disease-associated Pulmonary Arterial Hypertension.
Rhee RL; Gabler NB; Sangani S; Praestgaard A; Merkel PA; Kawut SM
Am J Respir Crit Care Med; 2015 Nov; 192(9):1111-7. PubMed ID: 26291092
[TBL] [Abstract][Full Text] [Related]
15. Evidence-based pharmacologic management of pulmonary arterial hypertension.
Benedict N; Seybert A; Mathier MA
Clin Ther; 2007 Oct; 29(10):2134-53. PubMed ID: 18042471
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of pulmonary arterial hypertension drugs in treatment-naive patients: a network meta-analysis.
Petrovič M; Locatelli I
J Comp Eff Res; 2020 Jan; 9(1):7-22. PubMed ID: 31845591
[No Abstract] [Full Text] [Related]
17. Efficacy and safety of novel-targeted drugs in the treatment of pulmonary arterial hypertension: a Bayesian network meta-analysis.
Fu W; He W; Li Y; Chen Y; Liang J; Lei H; Fu L; Chen Y; Ren N; Jiang Q; Shen Y; Ma R; Wang T; Wang X; Zhang N; Xiao D; Liu C
Drug Deliv; 2021 Dec; 28(1):1007-1019. PubMed ID: 34060401
[No Abstract] [Full Text] [Related]
18. Adverse Events in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.
Rhee RL; Gabler NB; Praestgaard A; Merkel PA; Kawut SM
Arthritis Rheumatol; 2015 Sep; 67(9):2457-65. PubMed ID: 26016953
[TBL] [Abstract][Full Text] [Related]
19. Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial.
White RJ; Jerjes-Sanchez C; Bohns Meyer GM; Pulido T; Sepulveda P; Wang KY; Grünig E; Hiremath S; Yu Z; Gangcheng Z; Yip WLJ; Zhang S; Khan A; Deng CQ; Grover R; Tapson VF;
Am J Respir Crit Care Med; 2020 Mar; 201(6):707-717. PubMed ID: 31765604
[No Abstract] [Full Text] [Related]
20. Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy.
Price LC; Howard LS
Am J Cardiovasc Drugs; 2008; 8(3):171-85. PubMed ID: 18533738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]